-Myc is a key transcriptional factor that has a prominent role in cell growth, differentiation and tumor development. Its protein levels are tightly controlled by ubiquitin-proteasome pathway and frequently deregulated in various cancers. Here, we report that the 11S proteasomal activator REGγ is a novel regulator of c-Myc abundance in cells. We showed that overexpression of wild-type REGγ, but not inactive mutants including N151Y and G250S, significantly promoted the degradation of c-Myc. Depletion of REGγ markedly increased the protein stability of c-Myc. REGγ interacts with the C-terminal region of c-Myc and regulates c-Myc protein turnover. Functionally, REGγ negatively regulates c-Myc-mediated cell proliferation. Interestingly, depletion of the Drosophila Reg homolog (dReg) in developing wings induced the upregulation of Drosophila Myc, which contributes to cell death. Collectively, these results suggest that REGγ proteasome has a conserved role in the regulation of Myc abundance in both mammalian cells and Drosophila.
Three proteasomal activators have been identified: 19S, PA200 and REG. 4, 5 The association of 20S with 19S forms the 26S proteasome, which is responsible for targeting most of the polyubiquitinated proteins for degradation in an ATPdependent manner. 3 The 20S proteasome can also be activated by association with the REG (also known as 11S or PA28). REG-activated 20S targets proteins for degradation in an ATP-and ubiquitin-independent manner. 6 Three evolutionarily conserved members of REG have been identified: REGα, REGβ and REGγ (alternatively named as PSME3 and Ki antigen). 5 REGα and REGβ are mainly localized in the cytoplasm and form heteroheptamers, which are mainly involved in MHC-1-mediated immune responses in immune cells. 6 In contrast, REGγ is predominantly localized within the nucleus and associated with 20S proteasome as a homoheptamer. 6 Recent studies indicate that REGγ can target intact proteins for degradation in an ubiquitin-and ATP-independent manner. 6 Several essential oncoproteins, including SRC-3 and PTTG1, as well as tumor suppressor proteins, such as p21 and p53, have been identified as REGγ targets. [7] [8] [9] [10] REGγ is involved in the regulation of cell growth, cell cycle and apoptosis. 6 REGγ is involved in the regulation of aging via p53 and regulates lipid metabolism via Sirt1 degradation. 11 REGγ also affects angiogenesis by regulating PKA activity. 12 REGγ is conserved in Drosophila and one Drosophila Reg (identified as dReg) has been identified. 13 However, the biological function of dReg is largely unknown.
The c-Myc transcription factor is a key regulator that stimulates cell proliferation, apoptosis and differentiation. [14] [15] [16] [17] Deregulated expression of c-Myc has been observed in a wide variety of human cancers. 18 c-Myc is a highly unstable protein and is usually degraded in o30 min in cells. 19, 20 Deregulated reduction of c-Myc protein degradation results in the accumulation of c-Myc in many cancers that may contribute to uncontrolled cell proliferation. 21 However, most reported pathways that control c-Myc protein degradation are ubiquitindependent proteasome pathways. 20 Several E3 ligases, including FBW7, SKP2, TRUSS, HectH9, β-Trcp1 and Hsc70-interacting protein (CHIP), have been identified as responsible for c-Myc degradation. 19, [22] [23] [24] [25] [26] [27] [28] However, it is still unclear whether c-Myc stability is regulated by ubiquitin-independent pathways. In the present study, we demonstrated that proteasome activator REGγ is a novel negative regulator of c-Myc and provided evidence that this regulation is evolutionarily conserved.
Results
REGγ degrades c-Myc. Previous evidence indicates that c-Myc protein levels are tightly controlled by multiple E3 ubiquitin ligases through ubiquitin-dependent protein degradation pathways under various cellular contexts. 19, 26 PSMD2, a key component of 19S lid, is required for ubiquitindependent protein degradation by the 26S proteasome. Knockdown of PSMD2 has been shown to be an approach to inhibit the 26S proteasome activity by inhibition of 19S function. 8, 29 To validate the role of the 26S proteasome in c-Myc degradation, we blocked the activity of the 26S proteasome in HeLa cells by inhibiting PSMD2 expression using PSMD2-specific siRNA as described previously. 8 The turnover of endogenous c-Myc protein was examined using a cycloheximide (CHX) chase assay. Surprisingly, we found that the inhibition of PSMD2 could not completely block the protein degradation of endogenous c-Myc in HeLa cells ( Figure 1a ). By contrast, the turnover of p53 and p27 proteins was markedly inhibited when PSMD2 was depleted ( Figure 1a ). These data suggest that a 26S proteasomeindependent pathway may exist to promote c-Myc degradation.
In addition to 19S lid, proteasome activator REG can form an 11S regulatory cap to activate the 20S proteasome. 6 REGγ is emerging as an alternative pathway to target intact proteins for degradation independent of the 26S proteasome.
7,30 Thus, we examined whether REGγ has any role in c-Myc protein turnover. Our data showed that ectopic expression of REGγ resulted in a marked reduction in c-Myc protein in a dosedependent manner (Figure 1b) . Ectopic expression of wildtype (WT), but not inactive mutant N151Y REGγ also promoted the degradation of endogenous c-Myc in HeLa cells (Figure 1c) . Furthermore, treatment with MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal), a potent proteasome inhibitor, completely blocked the REGγ-mediated c-Myc degradation (Figure 1d ), indicating that REGγ-promoted c-Myc degradation is dependent on the proteasome activity.
To further validate whether REGγ promotes c-Myc degradation independently of transcription, we set up a luciferasebased protein degradation (LPDS) reporter system (Supplementary Figure S1A) . The LPDS vector expresses a single transcript encoding firefly luciferase (FLuc) and Renilla luciferase (RLuc) separated by an internal ribosome entry site. Both FLuc and RLuc are quite stable and not rapidly destructed by the proteasome degradation pathway (Supplementary Figure S1B) . When fused with a short-lived protein to C terminus, the abundance of FLuc protein is controlled by the stability of the fused protein. In contrast, RLuc protein was not affected by the fusion because it is translated independent of FLuc. Therefore, the FLuc/RLuc ratio can reflect the turnover rate of the fused protein. Taking advantage of this system, we validated the role of REGγ in c-Myc degradation. Our data showed that REGγ had little effect on the FLuc/RLuc ratio when coexpressed with vector without fusion to any other protein (Supplementary Figure S1B) . In contrast, when fused with c-Myc to the C terminus of FLuc, the FLuc/RLuc ratio was markedly decreased by the coexpression of REGγ (Figure 1e ). Importantly, treatment with MG132 completely inhibited the effect of REGγ (Figure 1e ). This confirms that REGγ can indeed promote c-Myc degradation.
To further illustrate the specificity of REGγ, we evaluated the degradation of c-Myc by overexpressing c-Myc with REGα, REGβ, REGγ and REGα/β in 293T cells. As shown in Figure 1f , REGγ, but not REGα and REGβ, degraded c-Myc. As a proteasome activator, REGγ must associate with the 20S proteasome to promote protein degradation. 6 Mutation of Asn151 to Tyr (N151Y) or Gly150 to Ser (G150S) impairs the ability of REGγ to activate the 20S proteasome, but does not affect its binding to 20S proteasomes. 31 K188D is a hyperactive mutant that can activate trypsin-like, chymotrypsin-like and postglutamyl peptidyl hydrolyzing activity of the 20S proteasome. 32 As shown in Figure 1g , WT and hyperactive K188D, but not N151Y and G150S REGγ, markedly promoted c-Myc degradation. These results suggest that degradation of c-Myc by REGγ requires the activation of the 20S proteasome.
Endogenous c-Myc is regulated by REGγ in cancer cells. Next, we determined whether endogenous c-Myc is regulated by endogenous REGγ. To this end, REGγ was depleted using two independent siRNAs against REGγ in HeLa cells for 72 h. Western blotting analysis showed that endogenous cellular REGγ was efficiently depleted by both siRNAs. We found that endogenous c-Myc protein was markedly increased in REGγ-depleted cells (Figure 1h ). Stable knockdown of REGγ in HeLa cells also markedly increased the protein levels of both c-Myc and p21 (Figure 1h ). Similar results were obtained in MCF7 and 293T cells (Figure 1i ). Moreover, expression of an RNA interference (RNAi)-resistant WT REGγ, but not the inactive REGγN151Y, decreased the c-Myc protein (Figure 1j ), indicating that c-Myc protein stability was specifically regulated by REGγ expression and activity.
The effect of endogenous REGγ on the degradation of endogenous c-Myc was determined using a CHX chase assay. As shown in Figure 1k , the half-life of endogenous c-Myc protein was markedly prolonged upon REGγ knockdown. Moreover, knockdown of REGγ or FBW7 strikingly increased c-Myc stability in the LPDS assay (Supplementary Figure S1C) , confirming that c-Myc stability was regulated by endogenous REGγ.
Phosphorylation of c-Myc at Thr58 or Ser62 has been shown to be important for the ubiquitin-dependent degradation of c-Myc by FBW7. 19 However, our data indicated that T58A/ S62A was still degraded efficiently by REGγ (Supplementary Figure S1D) , suggesting that degradation of c-Myc by REGγ is independent of FBW7.
REGγ deficiency stabilizes c-Myc in MEFs. We further examined the regulation of c-Myc by REGγ using REGγ − / − (REGγ knockout) murine embryonic fibroblasts (MEFs). As expected, REGγ deficiency significantly increased the protein levels of c-Myc as well as the reported REGγ substrates p53 and p21, 10, 30 but had no measurable effect on the protein levels of AKT and LSD1 (Figure 2a ). This result was confirmed using an immunofluorescence staining assay (Figure 2b ). REGγ deficiency markedly increased c-Myc protein levels in the nuclei of MEFs (Figure 2b) . Moreover, our c-Myc associates with REGγ. Physical interaction between c-Myc and REGγ was determined using a co-IP assay. Our data showed that exogenous REGγ could interact with c-Myc in cells (Figure 3a) . Mutation of c-Myc Thr58 or Ser62 had no effect on its interaction with REGγ (Supplementary Figure  S3A) . We also examined the interaction between endogenous c-Myc and REGγ. HeLa cells were treated with MG132 and endogenous c-Myc was immunoprecipitated using an anti-c-Myc antibody. We found that REGγ could be readily detected in c-Myc immunoprecipitates (Figure 3b ). Endogenous c-Myc was also present in the endogenous REGγ immunoprecipitates (Figure 3c ). These data indicate that c-Myc can associate with REGγ in cells.
To define the domains in c-Myc that are responsible for its interaction with REGγ, we generated a series of c-Myc deletion mutants. Our data showed that REGγ interacted with those mutants containing the C-terminal domain including c-Myc (1-439 aa), c-Myc (143-439 aa) and c-Myc (251-439 aa). Thus, we conclude that the C-terminal domain of c-Myc is responsible for its interaction with REGγ ( Figure 3d ). The recent study indicated that stress can induce the production of an Myc-nick (short form of c-Myc), which promoted cell survival and autophagy. 33, 34 Our data indeed showed that Myc-nick was easily detected when cells were cultured at dense condition (Supplementary Figure S3C) . However, Myc-nick cannot bind to (Supplementary Figure  S3B) and be degraded by REGγ (Supplementary Figure S3C) . We also mapped the domains of REGγ involved in its interaction with c-Myc using a co-IP assay and in vitro pulldown assay. Our data indicated that both the N-and C-terminal regions of REGγ could interact directly with c-Myc, although with a weaker affinity than WT REGγ. (Figure 3e and Supplementary Figure S3D ). To examine whether multimer of REGγ is required for its binding to c-Myc, we coexpressed a mutant of REGγ K195R, which cannot form the multimer in cells. 35 Our data indicated that K195R mutant could still bind to c-Myc, but cannot degrade c-Myc anymore (Supplementary Figures S3E and F) . Collectively, these data indicate that c-Myc can physically interact with REGγ.
REGγ regulates c-Myc-mediated gene expression. c-Myc is a transcription factor that may regulate the transcription of numerous genes. 36 Because REGγ can promote the degradation of c-Myc, we examined whether REGγ affects c-Mycmediated gene expression using a luciferase reporter gene assay. It has been shown that expression of c-Myc can activate the promoter activity of RhoA and E2F1. 37, 38 Consistent with previous reports, 37, 39 expression of c-Myc strikingly increased the RhoA and E2F1 promoter activity ( Figure 4a ). As expected, the coexpression of REGγ significantly reduced the c-Myc-activated RhoA and E2F1 promoter activity. These data indicate that ectopically expressed REGγ can inhibit c-Myc transcriptional activity.
We also examined the effect of endogenous REGγ on c-Myc-mediated gene expression. Our data showed that knockdown of REGγ significantly increased the activity of RhoA promoter, which could be reversed by c-Myc knockdown (Figure 4b) . Moreover, knockdown of REGγ also increased the mRNA level of CDK4, a downstream target of c-Myc (Figure 4c) . Collectively, these results indicate that REGγ is a negative regulator of c-Myc-mediated gene expression.
REGγ inhibits c-Myc-induced cell proliferation. c-Myc is an essential factor that regulates cell proliferation. 17 Because REGγ can regulate the protein stability of c-Myc, we asked whether REGγ affects c-Myc-mediated cell proliferation. HeLa cells were transfected with c-Myc in the presence of WT or N151Y REGγ and cell proliferation was measured using a 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay. As expected, the expression of c-Myc in HeLa cells markedly (Figure 4f) .
We confirmed the role of REGγ in c-Myc-mediated cell growth using a soft-agar colony formation assay. Knockdown of REGγ in HeLa cells markedly increased the colonies number, which could be reversed by c-Myc knockdown (Figure 4g ). Taken together, these data suggest that REGγ is a negative regulator of c-Myc-mediated cell growth.
Regulation of dMyc stability by REG in Drosophila. REGγ has one Drosophila ortholog, dReg; 13 however, the biological function of dReg is largely unknown. Myc is a conserved transcriptional factor and has essential function in Drosophila. 40, 41 To examine whether dReg regulates Drosophila Myc (dMyc) level in Drosophila, we depleted dReg in Drosophila S2 cells and detected the dMyc protein level by western blotting. As shown in Figure 5a , depletion of dReg in S2 cells markedly increased dMyc protein levels. In addition, knockdown efficiency of dReg and dMyc transcriptional level was confirmed by q-PCR (Figure 5b) . Moreover, depletion of dReg in S2 cells prolonged the half-life of dMyc protein with the treatment of CHX at various time points (Figures 5c and d) .
To further examine whether dMyc is regulated by dReg in vivo, we performed a loss-of-function analysis of dReg in Drosophila using the Gal4-UAS system to drive the expression of a transgenic dReg RNAi line (UAS-dReg RNAi ) in a tissuespecific manner. 42 We used MS1096-Gal4 to deplete dReg in the entire wing pouch regions. Depletion of dReg using MS1096-Gal4 significantly increased dMyc protein detected by both immunostaining and western blotting assays ( Figures  5e, g and h) . Archipelago (Ago) is the Drosophila homolog of Fbw7 and Ago
RNAi was used as a positive control for dMyc stabilization. The dReg knockdown efficiency was confirmed using q-PCR (Figure 5f ). These results demonstrate that dReg is a negative regulator of dMyc. dReg promotes cell survival by preventing aberrant dMyc accumulation. Because upregulation of dMyc in Drosophila triggers cell-autonomous apoptosis, 41 we asked whether loss of dReg provokes cell death via dMyc upregulation. To this end, we depleted dReg in the dorsal compartment of wing discs using apterous-Gal4 (ap-Gal4). UAS-GFP was coexpressed to mark the cells with dReg depleted. dMyc protein was uniformly distributed in the dorsal and ventral compartments in the control wing discs (Figures 6a and b) . As expected, dMyc protein level was markedly increased in dorsal compartment cells where dReg was depleted (Figures   6d and e) . We monitored apoptosis using an antibody against activated caspase-3 and found that dorsal compartment cells with dReg depleted contained excessive number of caspase-3-positive cells, which were barely detected in control discs (compare Figure 6c with Figure 6f ).
To determine whether elevated dMyc in dReg-depleted cells contribute to cell death, we knocked down dMyc by RNAi either in control or dReg-depleted discs. dMyc knockdown was confirmed by staining the discs with the dMyc antibody (Figures 6j and k) . Although dMyc RNAi alone did not have a significant effect on cell death (Figure 6l ), dMyc RNAi in dReg depletion discs prevented the upregulation of dMyc and greatly reduced the number of caspase-3-positive cells (Figures 6g-i) , suggesting that dReg promotes cell survival at least in part by preventing the abnormal accumulation of dMyc. Coexpression of the cell death inhibitor Diap1 with dReg RNAi blocked apoptosis but did not block the upregulation of dMyc (Figures 6m-o) , suggesting that upregulation of dMyc in dReg-depleted cells is not secondary to cell death but instead may reflect a direct regulation of dMyc by dReg. Consistent with this, we found that an HA-tagged dReg formed a complex with a Flag-tagged dMyc when coexpressed in S2 cells (Supplementary Figure S4) . Taken together, our data indicate that Reg has a conserved role in regulating Myc abundance.
Loss of dReg causes developmental defects. We further used the Gal4-UAS system, which can drive the expression of a transgenic dReg RNAi line (UAS-dReg RNAi ) in a tissuespecific manner, to analyze the phenotype caused by dReg loss-of-function in Drosophila. We used ap-Gal4 driver to specifically deplete dReg in the dorsal compartment of the wing (Figures 7a and b) , MS1096-Gal4 to deplete dReg in the whole wing pouch regions (Figures 7c and d) and Hh-Gal4 to induce UAS-RNAi expression in the posterior part of the wing (Figures 7e and f) . Our data indicated that depletion of dReg in the wing resulted in the smaller wing size compared with the control wing (Figures 7a-d) . Moreover, dReg depletion by Hh-Gal4 driver had marked ablation of posterior wing phenotype (Figures 7e and f) . Furthermore, loss of dReg expression in Drosophila eye elicited by eyeless-Gal4 showed smaller eye phenotype (Figures 7g and h) . In summary, we demonstrate that dReg expression is involved in normal development likely by regulating apoptosis through dMyc.
Discussion
As an essential transcription factor, the protein levels of c-Myc are tightly controlled by multiple E3 ubiquitin ligases through ubiquitin-dependent pathways. 20 In this study, we identified a novel ubiquitination-independent pathway regulating the protein levels of c-Myc. We found that the proteasome activator REGγ controls the abundance of c-Myc proteins by regulating protein stability. REGγ interacts with c-Myc and promotes its turnover in cells. REGγ inhibits c-Myc-mediated gene expression and cell growth. In addition, regulation of Myc stability by dReg is essential for Drosophila development. Thus, our study suggests that REGγ and dReg are novel and conserved regulators of Myc proteins.
As a component of 11S cap, it was originally recognized that REGγ only has the ability to degrade unfolded proteins or small peptides by activating the 20S proteasome. 6 However, this idea has been challenged by the recent discovery that REGγ can degrade intact oncoprotein SRC-3. 7 Following that finding, more proteins, such as p21, ARF, p14, MAFA, and AID, were found to be degraded by REGγ. 8, 30, 43, 44 Interestingly, REGγ can degrade oncoproteins including SRC-3 and PTTG1, as well as tumor suppressors including p21, ARF and p53. [7] [8] [9] [10] Thus, it is expected that REGγ has a context-dependent role in tumorigenesis. Indeed, studies indicated that REGγ is absent in breast cancers but upregulated in thyroid cancers. 7, 45 Our study revealed that the oncoprotein c-Myc is a novel substrate of REGγ. We found that c-Myc protein is negatively regulated by REGγ in several cancer cell lines, including HeLa, MCF7 and MEFs. Deregulation of c-Myc protein stability has been shown to be related to tumorigenesis. 17 Our data clearly showed that knockdown of REGγ promoted the cell proliferation of cancer cells via a different in different types of cells, which may contribute to the cell-type-specific regulation of c-Myc stability by REGγ. It is also possible that REGγ-mediated c-Myc degradation is regulated by context-dependent extracellular signaling events. 46 In addition, some unidentified regulators may affect the regulation of c-Myc by REGγ. Thus, more studies will be required to characterize the regulation of c-Myc by REGγ under different physiological and pathological conditions in future.
The regulation of Myc by REGγ appears to be conserved in Drosophila. We found that dReg interacted with dMyc and that dReg depletion increased the stability of dMyc in cultured cells. In addition, we found that dReg depletion in wing discs upregulated dMyc protein levels, leading to apoptosis. These results suggest that dReg promotes cell survival in Drosophila development by preventing abnormal dMyc accumulation. Our study on the regulation of Myc by REGγ in Drosophila not only demonstrated the physiological relevance but also the evolutionary conservation of this regulatory mechanism.
Materials and Methods Plasmids. The expression plasmids of WT and N151Y REGγ were described previously. 30 RhoA promoter reporter was kindly provided by Dr. Hui-Kuan Lin.
37
E2F1 promoter reporter was kindly provided by Dr. Mu-Shui Dai. 39 Mouse c-Myc plasmids were amplified using PCR and cloned into pcDNA3.1 with an HA tag at the N terminus. Point mutations and deletion mutants of c-Myc and REGγ were cloned using PCR-based standard cloning method. GFP-tagged REGγ deletion mutants were kindly provided by Dr. Chuangui Wang (East China Normal University, Shanghai, China). 11 Lentivirus vectors were produced by subcloning REGγ and its mutants into PLVX-ZsGreen lentivirus vector. The LPDS system was produced by subcloning firefly and Renilla CDS into pcDNA3.1 vector. c-Myc was subcloned into the C terminus of FLuc. All the vectors were confirmed using DNA sequencing.
Reagents. Antibodies against p21 (no. 2136), p53 (no. 9282), LSD1 (no. 2139), AKT (no. 9272) and p27 (no. 2552) were obtained from Cell Signaling Technology (Danvers, MA, USA). c-Myc (no. 1472-1) antibody was purchased from Epitomics (Burlingame, CA, USA). The Myc 274 antibody against Myc-nick is a generous gift from Naohiko Ikegaki (University of Illinois, Champaign, IL, USA). 33 Anti-actin (sc-8432), REGγ (sc133876), c-Myc (9E10) (sc-40) and PSMD2 (sc-68352) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HA (H3663), Flag (F1840) and GFP (G1546) antibodies, CHX (C4859) and MG132 (M7449) were all purchased from Sigma (St. Louis, MO, USA). Dual-Luciferase Reporter System Kit (E1501) and TNT (L5020) were purchased from Promega (Madison, WI, USA).
Cell culture and transfections. Human embryonic kidney 293T (HEK293T) cells and human epithelial carcinoma HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in 5% CO 2 . MEFs were isolated from E13.5-day REGγ +/+, REGγ − / − mouse embryos. Immortalized MEFs were described in a previous report. 30 All cell lines were cultured in DMEM supplemented with 10% FBS (HyClone, Logan, UT, USA). Transfections were performed using the calcium phosphate-DNA co-precipitation method for HEK293T cells, and SunbioTrans-EZ for HeLa cells.
RNA interference. Three different siRNAs against REGγ were used: siRNA no. 1 -5′-GAAUCAAUAUGUCACUCUAUU-3′ and siRNA no. 2 -5′-UCUG AAGGAACCAAUCUUAUU-3′. siRNA no. 3: 5′-GGGAACUAUUUCUCUUUAUTT-3′ and the siRNA against c-Myc was: 5′-CAUCAUCAUCCAGGACUGUAU-3′. PSMD2 siRNAs used were as follows: no. 1: 5′-GCGACCUGCUUAU;GGAAAUTT-3′ and no. 2: 5′-CCACUAUCCUUCAGACCAUTT-3′.
CHX chase assay. The siRNAs were transfected into cells using Lipofectamine 2000 following the manufacturer's instruction. At 72 h after transfection, cells were treated with 50 μg/ml CHX for the indicated times. Then, the cells were lysed and prepared for western blotting analysis. c-Myc levels relative to time point 0 are shown in all graphs of CHX experiments. Loss of dReg expression in Drosophila eye by eyeless-Gal4 showed a significantly smaller eye. WT control was driven by using each of Gal4
